CL2018000043A1 - Anticuerpos de unión a tau - Google Patents

Anticuerpos de unión a tau

Info

Publication number
CL2018000043A1
CL2018000043A1 CL2018000043A CL2018000043A CL2018000043A1 CL 2018000043 A1 CL2018000043 A1 CL 2018000043A1 CL 2018000043 A CL2018000043 A CL 2018000043A CL 2018000043 A CL2018000043 A CL 2018000043A CL 2018000043 A1 CL2018000043 A1 CL 2018000043A1
Authority
CL
Chile
Prior art keywords
binding antibodies
tau binding
tau
antibodies
union
Prior art date
Application number
CL2018000043A
Other languages
English (en)
Inventor
Terence Seward Baker
Robert Anthony Griffin
Georges Mairet-Coello
Patrick Downey
David Edward Ormonde Knight
David James Mcmillan
Jean-Phillippe Courade
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53524640&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2018000043(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of CL2018000043A1 publication Critical patent/CL2018000043A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

<p>LA PRESENTE INVENCIÓN SE REFIERE A ANTICUERPOS DE UNIÓN A TAU Y FRAGMENTOS DE UNIÓN DE LOS MISMOS.</p>
CL2018000043A 2015-07-06 2018-01-05 Anticuerpos de unión a tau CL2018000043A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15175522 2015-07-06

Publications (1)

Publication Number Publication Date
CL2018000043A1 true CL2018000043A1 (es) 2018-05-18

Family

ID=53524640

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018000043A CL2018000043A1 (es) 2015-07-06 2018-01-05 Anticuerpos de unión a tau

Country Status (28)

Country Link
US (4) US10287343B2 (es)
EP (1) EP3319983A1 (es)
JP (3) JP6630426B2 (es)
KR (1) KR20180025962A (es)
CN (1) CN107849104B (es)
AR (1) AR105267A1 (es)
AU (1) AU2016289755C1 (es)
BR (1) BR112017028102A2 (es)
CA (1) CA2991451A1 (es)
CL (1) CL2018000043A1 (es)
CO (1) CO2017012971A2 (es)
EA (1) EA037092B1 (es)
EC (1) ECSP18000887A (es)
HK (1) HK1246804A1 (es)
IL (1) IL256685B (es)
MA (2) MA42377A (es)
MX (1) MX2017015817A (es)
MY (1) MY193677A (es)
NZ (1) NZ738058A (es)
PE (1) PE20180481A1 (es)
PH (1) PH12017502207A1 (es)
SG (1) SG10202010735PA (es)
TN (1) TN2017000539A1 (es)
TW (1) TWI745295B (es)
UA (1) UA124616C2 (es)
UY (1) UY36773A (es)
WO (1) WO2017005734A1 (es)
ZA (1) ZA201800027B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201911349YA (en) 2015-06-05 2020-01-30 Genentech Inc Anti-tau antibodies and methods of use
MX2017015908A (es) 2015-07-06 2018-03-15 Ucb Biopharma Sprl Anticuerpos de union a tau.
UA124616C2 (uk) 2015-07-06 2021-10-20 Юсб Біофарма Срл Зв'язуюче тау-білок антитіло
EP3551220A1 (en) 2016-12-07 2019-10-16 Genentech, Inc. Anti-tau antibodies and methods of use
KR102645073B1 (ko) 2016-12-07 2024-03-11 제넨테크, 인크. 항-타우 항체 및 이의 이용 방법
BR112019017021A2 (pt) 2017-02-17 2020-04-14 Denali Therapeutics Inc anticorpos anti-tau e métodos de uso dos mesmos
JP2018139530A (ja) 2017-02-27 2018-09-13 帝人ファーマ株式会社 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
TWI809562B (zh) 2017-10-16 2023-07-21 日商衛材R&D企管股份有限公司 抗tau抗體及其用途
EP3894438A1 (en) * 2018-12-13 2021-10-20 INSERM (Institut National de la Santé et de la Recherche Médicale) New anti tau svqivykpv epitope single domain antibody
EP4013772A1 (en) * 2019-08-13 2022-06-22 Washington University Methods to detect mtbr tau isoforms and use thereof
EP4103615A1 (en) 2020-02-12 2022-12-21 Eli Lilly and Company Crystallization of antibodies or antigen-binding fragments
CA3183835A1 (en) 2020-06-25 2021-12-30 Jeanne E. Baker High affinity antibodies targeting tau phosphorylated at serine 413
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US6566329B1 (en) 1999-06-28 2003-05-20 Novo Nordisk A/S Freeze-dried preparation of human growth hormone
AT500379B8 (de) * 2001-02-02 2009-08-15 Axon Neuroscience Tau-proteine
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
PL1644412T5 (pl) 2003-07-01 2019-01-31 Ucb Biopharma Sprl Modyfikowane fragmenty Fab przeciwciała
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
CN1721437A (zh) * 2004-07-13 2006-01-18 中南大学 一种与Tau蛋白相关的多肽抗原及抗体
EP2500352A1 (en) 2005-08-19 2012-09-19 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
GB0614780D0 (en) 2006-07-25 2006-09-06 Ucb Sa Biological products
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
EP2195341B1 (en) 2007-09-26 2017-03-22 UCB Biopharma SPRL Dual specificity antibody fusions
CN101307108B (zh) * 2008-06-25 2012-04-04 南京川博生物技术有限公司 抗磷酸化Tau蛋白抗体及其在AD症异常磷酸化Tau蛋白水平测定上的用途
WO2010035012A1 (en) 2008-09-26 2010-04-01 Ucb Pharma S.A. Biological products
RU2011118056A (ru) 2008-10-15 2012-11-27 Ангиокем Инк. Конъюгаты агонистов glp-1 и их применение
CA2745524C (en) 2008-12-05 2020-06-09 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
MX2011005965A (es) 2008-12-05 2011-09-01 Angiochem Inc Conjugados de leptina y de análogos de leptina y sus usos de los mismos.
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
EP2475682B1 (en) 2009-09-10 2018-01-31 UCB Biopharma SPRL Multivalent antibodies
CN102781965A (zh) 2009-10-06 2012-11-14 安吉奥开米公司 用于转运治疗剂的组合物和方法
JP6371526B2 (ja) 2010-10-07 2018-08-08 エーシー イミューン エス．エー． タウを認識するリン酸化部位特異的抗体
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
SG10201703771WA (en) 2011-09-19 2017-06-29 Axon Neuroscience Se Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease
CA2856216C (en) 2011-11-11 2021-01-12 Ucb Pharma S.A. Albumin binding antibodies and binding fragments thereof
SG11201403106SA (en) * 2011-12-20 2014-12-30 Janssen Biotech Inc Anti-phf-tau antibodies and their uses
RU2018132044A (ru) 2012-07-03 2018-10-19 Вашингтон Юниверсити Антитела против тау
AU2013302540B2 (en) 2012-08-16 2018-02-15 Ipierian, Inc. Methods of treating a tauopathy
ES2816700T3 (es) 2012-12-21 2021-04-05 Biogen Ma Inc Anticuerpos anti-tau humanos
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
MX2017015908A (es) 2015-07-06 2018-03-15 Ucb Biopharma Sprl Anticuerpos de union a tau.
UA124616C2 (uk) 2015-07-06 2021-10-20 Юсб Біофарма Срл Зв'язуюче тау-білок антитіло

Also Published As

Publication number Publication date
SG10202010735PA (en) 2020-11-27
AU2016289755C1 (en) 2021-08-19
AU2016289755A1 (en) 2018-01-04
MX2017015817A (es) 2018-04-10
ZA201800027B (en) 2019-06-26
JP2018524001A (ja) 2018-08-30
JP7100008B2 (ja) 2022-07-12
CN107849104A (zh) 2018-03-27
PE20180481A1 (es) 2018-03-07
JP7413448B2 (ja) 2024-01-15
AR105267A1 (es) 2017-09-20
JP2022141689A (ja) 2022-09-29
PH12017502207A1 (en) 2018-06-11
US10889640B2 (en) 2021-01-12
US20210115121A1 (en) 2021-04-22
UY36773A (es) 2017-01-31
EP3319983A1 (en) 2018-05-16
IL256685A (en) 2018-03-29
MY193677A (en) 2022-10-25
CA2991451A1 (en) 2017-01-12
UA124616C2 (uk) 2021-10-20
AU2016289755B2 (en) 2020-12-03
HK1246804A1 (zh) 2018-09-14
US11732034B2 (en) 2023-08-22
US20230416350A1 (en) 2023-12-28
EA201890172A1 (ru) 2018-10-31
WO2017005734A1 (en) 2017-01-12
EA037092B1 (ru) 2021-02-04
IL256685B (en) 2022-02-01
JP2020055849A (ja) 2020-04-09
US20180201666A1 (en) 2018-07-19
CO2017012971A2 (es) 2018-03-09
NZ738058A (en) 2021-07-30
CN107849104B (zh) 2021-08-27
ECSP18000887A (es) 2018-03-31
TW201713689A (zh) 2017-04-16
JP6630426B2 (ja) 2020-01-15
BR112017028102A2 (pt) 2018-09-04
US10287343B2 (en) 2019-05-14
KR20180025962A (ko) 2018-03-09
TN2017000539A1 (en) 2019-04-12
MA41670A1 (fr) 2018-05-31
MA42377A (fr) 2018-05-16
US20190284267A1 (en) 2019-09-19
TWI745295B (zh) 2021-11-11

Similar Documents

Publication Publication Date Title
CL2018000042A1 (es) Anticuerpos de unión a tau
CL2018000043A1 (es) Anticuerpos de unión a tau
MX2022005173A (es) Anticuerpos anti-promiostatina o miostatina latente y usos de los mismos.
CL2018000595A1 (es) Anticuerpos anti-pd1 y métodos de uso
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
MD3827845T2 (ro) Formulări subcutanate de anticorpi anti-CD38 și utilizări ale acestora
CL2017000545A1 (es) Anticuerpos anti-her2 e inmunoconjugados
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
MA46057A (fr) Anticorps anti-ctla4
CL2016000460A1 (es) Proteínas de unión al antígeno gitr
EA201691610A8 (ru) Анти-jagged1 антитела и способы применения
EA201691974A1 (ru) Антитела против ox40 и способы их применения
CU20170074A7 (es) Anticuerpos heterodiméricos que se unen a cd3 y a antígenos tumorales
GT201700131A (es) Composiciones y métodos para anticuerpos dirigidos a bmp6
DK3313845T3 (da) Konjugater af cysteinmanipulerede antistoffer
DK3606961T3 (da) Garp-tgf-beta-antistoffer
JP2016525099A5 (ja) 免疫グロブリンＦｃ断片のＦｃＲｎに対する結合親和力が維持される免疫グロブリンＦｃ結合体
MX2016016233A (es) Anticuerpos anti-lgr5 y sus usos.
MA43715A (fr) Anticorps anti-tnf et fragments fonctionnels correspondants
MA50654A (fr) Anticorps anti-pacap
MA49289A (fr) Anticorps se liant à steap-1
MA49257A (fr) Anticorps anti-trkb
DK3356398T3 (da) Fremgangsmåde til udvikling af monoklonale antistoffer
TH1601003730A (th) แอนติ-vista แอนติบอดี และชิ้นส่วนย่อย
TH1601002706A (th) แอนทิบอดีที่จำเพาะต่อ FcRn